Abstract
Endothelin-1 (ET-1), which acts through the endothelin A receptor (ETAR) or ETBR, belonging to the large family of G-protein coupled receptors (GPCR), is involved in physiopathological processes, such as cancer. In epithelial ovarian cancer, a pervasively activated ET-1/ETAR axis drives different steps of tumor progression and confers drug resistance. In this malignancy, one major aspect associated with the ETAR signaling machinery resides in the fact that this receptor may use β-arrestin-1 (β-arr1) function to spatially and temporally activate key oncogenic pathways. This results in specificity of ET-1/ETAR signal transduction mechanisms and downstream signaling pathways. As such, β-arr1 has been recognized as an important signal transducer involved in multiple cross talks with other signaling pathways, including those activated by tyrosine kinase receptors. The interaction with diverse sets of partners positions β-arr1 as a critical regulator of GPCR signal transduction and permits the integration of ETAR-mediated signals with other cytoplasmic or nuclear inputs. In particular, the scaffolding function of β-arr1 provides an essential link in translating ETAR function by altering β-catenin localization and function, promoting β-catenin-related transcriptional activity and gene transcription relevant to tumor progression. This chapter outlines the methodologies for the measurement of β-arr1/β-catenin protein interactions and functional activity in tumor cells.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Masaki T, Vane JR, Vanhoutte PM (1994) International Union of Pharmacology nomenclature of endothelin receptors. Pharmacol Rev 46:137–142
Nelson J, Bagnato A, Battistini B, Nisen P (2003) The endothelin axis: emerging role in cancer. Nat Rev Cancer 3:110–116
Rosanò L, Spinella F, Bagnato A (2013) Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 13:637–651
Peterson YK, Luttrell LM (2017) The diverse roles of arrestin scaffolds in G protein-coupled receptor signaling. Pharmacol Rev 69:256–297
Shenoy SK, Lefkowitz RJ (2011) β-Arrestin-mediated receptor trafficking and signal transduction. Trends Pharmacol Sci 32:521–533
Rosanò L, Bagnato A (2016) β-arrestin1 at the cross-road of endothelin-1 signaling in cancer. J Exp Clin Cancer Res 35:121–113
Purayil HT, Zhang Y, Dey A, Gersey Z, Espana-Serrano L, Daaka Y (2015) Arrestin2 modulates androgen receptor activation. Oncogene 34:3144–3151
Qin R, Li K, Qi X, Zhou X, Wang L, Zhang P et al (2014) β-Arrestin1 promotes the progression of chronic myeloid leukaemia by regulating BCR/ABL H4 acetylation. Br J Cancer 111:568–576
Zecchini V, Madhu B, Russell R, Pértega-Gomes N, Warren A, Gaude E, Borlido J et al (2014) Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO J 33:1365–1382
Shenoy SK, Han S, Zhao YL, Hara MR, Oliver T, Cao Y, Dewhirst MW et al (2012) β-arrestin1 mediates metastatic growth of breast cancer cells by facilitating HIF-1-dependent VEGF expression. Oncogene 31:282–292
Rosanò L, Cianfrocca R, Masi S, Spinella F, Di Castro V, Biroccio A et al (2009) Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A 106:2806–2811
Cianfrocca R, Rosanò L, Spinella F, Di Castro V, Natali PG, Bagnato A (2010) Beta-arrestin-1 mediates the endothelin-1-induced activation of Akt and integrin-linked kinase. Can J Physiol Pharmacol 88:796–801
Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Spadaro F et al (2013) β-Arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene 32:5066–5077
Cianfrocca R, Tocci P, Semprucci E, Spinella F, Di Castro V, Bagnato A et al (2014) β-Arrestin 1 is required for endothelin-1-induced NF-κB activation in ovarian cancer cells. Life Sci 118:179–184
Rosanò L, Cianfrocca R, Tocci P, Spinella F, Di Castro V, Caprara V et al (2014) Endothelin A receptor/β-arrestin signalling to the Wnt pathway renders ovarian cancer cells resistant to chemotherapy. Cancer Res 74:7453–7464
Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M et al (2016) Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene 35:3432–3442
Cianfrocca R, Tocci P, Rosanò L, Caprara V, Sestito R, Di Castro V et al (2016) Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression. Oncotarget 7:17790–17804
Cianfrocca R, Rosanò L, Tocci P, Sestito R, Caprara V, Di Castro V et al (2017) Blocking endothelin-1-receptor/β-catenin circuit sensitizes to chemotherapy in colorectal cancer. Cell Death Differ 24(10):1811–1820. https://doi.org/10.1038/cdd.2017.121
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rosanò, L., Cianfrocca, R., Bagnato, A. (2019). Methods to Investigate β-Arrestin-1/β-Catenin Signaling in Ovarian Cancer Cells. In: Scott, M., Laporte, S. (eds) Beta-Arrestins. Methods in Molecular Biology, vol 1957. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-9158-7_25
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9158-7_25
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-9157-0
Online ISBN: 978-1-4939-9158-7
eBook Packages: Springer Protocols